SYBX
- Synlogic, Inc.
()
Overview
Company Summary
Synlogic, Inc. is a biotechnology company that is focused on developing novel therapeutics based on synthetic biology. The company harnesses the power of engineered microbes, or synthetic bacteria, to deliver targeted therapies for various diseases and disorders.
Synlogic's approach involves designing and engineering bacteria to perform specific functions within the human body. These synthetic bacteria are engineered to produce therapeutic molecules, metabolize specific compounds, or interact with the body's natural biological processes to treat disease.
The company's pipeline includes programs targeting a range of diseases, including inborn errors of metabolism (IEMs), cancer, and immune-mediated disorders. For example, Synlogic is developing therapies for phenylketonuria (PKU), a rare genetic disorder that affects the body's ability to metabolize the amino acid phenylalanine. By introducing synthetic bacteria that can metabolize phenylalanine, Synlogic aims to reduce the levels of this amino acid in the body and alleviate the effects of PKU.
Synlogic combines its expertise in synthetic biology, computational modeling, and clinical development to create and advance these novel therapies. The company conducts preclinical and clinical trials to evaluate the safety and efficacy of its synthetic bacterial treatments, with the ultimate goal of bringing these therapies to patients in need.
Overall, Synlogic is at the forefront of using synthetic biology to tackle complex diseases by leveraging the power of engineered microbes. Their innovative approach has the potential to transform the treatment landscape for a variety of conditions, providing more targeted and effective therapeutic options for patients.